Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,017 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Infection Clear all

Conditions: Critical Illness, Sepsis, Multiple Organ Failure
Interventions: Glutamine, Antioxidants, Glutamine + Antioxidants, Placebo; Other
Lead sponsor: Daren K. Heyland; Other
Eligibility: 18 Years and older
Enrollment: 1,223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 5
States / cities: Aurora, Colorado • Louisville, Kentucky • Dayton, Ohio + 2 more

Conditions: New Onset Atrial Fibrillation, Sepsis, Respiratory Failure
Interventions: Amiodarone in Parenteral Dosage Form, Amiodarone Pill, Direct Current Cardioversion (DCC), Rate-control therapy; Drug · Procedure
Lead sponsor: Our Lady of the Lake Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Sepsis
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, sargramostim, cyclophosphamide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Chronic Hepatitis b, Viremia
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Staphylococcal Sepsis
Interventions: Placebo, BSYX-A110; Drug
Lead sponsor: Biosynexus Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sepsis, Hypotension
Interventions: Drotrecogin Alfa (Activated), placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Sepsis, Community Acquired Pneumonia (CAP)
Interventions: OPT101, Placebo; Drug · Other
Lead sponsor: Op-T LLC; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Sepsis, Trauma
Interventions: Not listed
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Bamberg, South Carolina • Barnwell, South Carolina • Charleston, South Carolina + 2 more

Conditions: Sepsis, Severe Sepsis, Septic Shock
Interventions: Sepsis Watch; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 32,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neonatal Sepsis
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 3 Days and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Charlottesville, Virginia

Conditions: Bloodstream Infection
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 24 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Pneumonia, Blood Stream Infection, Urinary Tract Infections, Respiratory Tract Infection (Including Tracheobronchitis), Sepsis
Interventions: Not listed
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York

Conditions: Sepsis
Interventions: Suspected Sepsis Group - Diagnostic Measurements, Control Group - Diagnostic Measurements; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions: AP-SA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 23
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more

Conditions: Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions: Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 29
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more

Conditions: SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 110 Years
Enrollment: 114 participants
Timeline: 1995 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sepsis Syndrome, Sepsis, Severe Sepsis, Septic Shock, Infection
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 1,304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Covid19, Sepsis, Adults, Emergency Department
Interventions: CBC-Diff Monocyte Volume Width Distribution; Device
Lead sponsor: Beckman Coulter, Inc.; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 32 participants
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Aids-related Malignancies, Lymphoma, Precancerous Condition, Sarcoma
Interventions: polymerase chain reaction, cytology specimen collection procedure, histological technique, colposcopic biopsy; Genetic · Other · Procedure
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Etoposide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Conditions: Foot Ulcer, Diabetic, Infection
Interventions: Gentamicin Collagen sponge, Placebo; Drug · Other
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Anniston, Alabama • Las Vegas, Nevada

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: alemtuzumab, methylprednisolone, prednisone, flow cytometry, immunologic technique, pharmacological study; Biological · Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Nosocomial Infection, Bacteremia, Sepsis, Pneumonia, Urinary Tract Infection, Clostridium Infection
Interventions: 2% chlorhexidine gluconate impregnated cloth, Daily bathing with Bar soap; Drug · Other
Lead sponsor: Cook County Health; Government
Eligibility: 16 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients

Rapid Atrial Fibrillation Treatment Strategy

The Ohio State University Sepsis Registry

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

Adaptability of an Undetectable = Untransmissible Model for HBV

Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants

Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

Critical Care Excellence in Sepsis and Trauma

Implementation and Evaluations of Sepsis Watch

Improved Detection of Neonatal Sepsis Using a Targeted Biomarker Assay

Next Generation Pathogen Sequencing for Prediction of Adverse Events

Optimizing Clinical Use of Polymyxin B

Mitochondrial Dysfunction Contributes to Sepsis Induced Cardiac Dysfunction

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

Mitochondrial DNA as a Biomarker of Sepsis Severity

Feasibility Study of Hematology Parameters in COVID-19 Disease

Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections